ABPO
Abpro Holdings, Inc.
- PER (TTM)
- -
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.06
- 시가총액
- 1.12M
- 배당수익률
- -
- 베타
- 0.15
- 1개월 수익률
- 82.69%
- 3개월 수익률
- -87.33%
- 6개월 수익률
- -96.58%
- 1년 수익률
- -97.13%
- 2년 수익률
- -
- 5일 평균거래량
- 32600
- 60일 평균거래량
- 194842
- 1년 평균거래량
- 617650
- 5d/60d 거래량 비율
- 0.17×
- 60d/1y 거래량 비율
- 0.32×
- 변동성(60일, 연환산)
- 293.30%
- BB 스퀴즈 스코어
- 1.13
- SMA50 비율
- 1.35
- SMA200 비율
- 0.05
- RSI (14)
- 49
- 20일 수렴도
- 0.18
- 52주 최고
- 9.69
- 52주 최저
- 0.10
- 고점 대비
- -98.04%
- 저점 대비
- 90.00%
펀더멘털 갱신: 2026-05-10T07:27:09+00:00 · 시세 갱신: 2026-05-10T06:07:27+00:00
회사 정보
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.